CSL RAI 2026: Accelerating Translational Research

CSL Research Acceleration Initiative 2026

Supporting the translation of innovative research into therapies

The Fondation pour Recherches Médicales is pleased to share the CSL Research Acceleration Initiative (RAI) 2026, an international funding program designed to support early-stage biotech companies and academic research organizations in advancing innovative therapeutic projects.

Led by CSL, a global biotechnology company dedicated to developing therapies for serious and life-threatening diseases, the initiative aims to accelerate the translation of cutting-edge research into clinical solutions.

Financial and scientific support

Selected projects may receive:

• up to USD 400,000 in non-dilutive funding over two years,
• support from a dedicated CSL scientific champion,
• access to CSL’s global expertise, technologies and capabilities,
• opportunities for scientific collaboration and joint publications.

Since 2020, the program has resulted in more than 270 publications with academic and biotech partners worldwide.

Targeted therapeutic areas

The 2026 call focuses on projects aligned with CSL’s strategic therapeutic areas, including:

• transplant and immunology,
• hematology,
• rare cardiovascular and renal diseases,
• gene therapy and next-generation therapeutic approaches,
• innovative oral delivery technologies for biologics,
• patient-centric therapeutic solutions.

Key dates

Interested researchers are invited to:

• attend an information webinar
  • 20 January 2026 at 4:00 PM CET
  • 3 February 2026 at 11:00 AM CET
• submit a non-confidential 500-word abstract via the CSL online portal
• application deadline: 24 February 2026

The CSL Research Acceleration Initiative represents a unique opportunity for translational research teams seeking to maximize the clinical impact of their work through collaboration with a leading global biotech partner.

‍